The global focal segmentmental glomerulosclerosis (FSGS) treatments market sales is expected to expand at a compound annual growth rate (CAGR) of 5% between 2023 and 2033, from US$ 3 billion in 2023 to US$ 4.89 billion by 2033. From 2018 to 2022, Focal Segmental Glomerulosclerosis (FSGS) Therapeutics’ market share increased at a compound annual growth …